1. Home
  2. EPR vs CRNX Comparison

EPR vs CRNX Comparison

Compare EPR & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EPR Properties

EPR

EPR Properties

HOLD

Current Price

$62.04

Market Cap

4.6B

Sector

Real Estate

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$83.90

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPR
CRNX
Founded
1997
2008
Country
United States
United States
Employees
54
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
EPR
CRNX
Price
$62.04
$83.90
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$58.94
$76.75
AVG Volume (30 Days)
531.8K
6.0M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
6.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$2.66
$720.10
Revenue Next Year
$8.60
$184.67
P/E Ratio
$25.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.11
$25.83
52 Week High
$63.30
$84.00

Technical Indicators

Market Signals
Indicator
EPR
CRNX
Relative Strength Index (RSI) 66.74 92.96
Support Level $57.44 $40.74
Resistance Level N/A N/A
Average True Range (ATR) 1.04 0.66
MACD 0.26 1.48
Stochastic Oscillator 75.54 99.75

Price Performance

Historical Comparison
EPR
CRNX

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: